Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
http://dx.doi.org/10.25673/115161
Langanzeige der Metadaten
DC Element | Wert | Sprache |
---|---|---|
dc.contributor.author | Wohlrab, Johannes | - |
dc.contributor.author | Kegel, Thomas | - |
dc.contributor.author | Große, Regina | - |
dc.contributor.author | Eichner, Adina | - |
dc.date.accessioned | 2024-03-05T07:23:01Z | - |
dc.date.available | 2024-03-05T07:23:01Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | https://opendata.uni-halle.de//handle/1981185920/117117 | - |
dc.identifier.uri | http://dx.doi.org/10.25673/115161 | - |
dc.description.abstract | In accordance with article 20 of Regulation (EC) No 726/2004, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has re-evaluated the safety of Janus kinase inhibitors for the treatment of inflammatory diseases and formulated safety information deviating from the previous indications in the respective summary of product characteristics of the products concerned. These refer to the consideration of a possibly increased risk of venous thromboembolic or severe cardiovascular events, an increased infection rate and an increase in the prevalence of skin cancer across drugs and indications. Therefore, in patients with independent risk factors (age 65 years and older, smokers or former smokers, patients with oral contraception or hormone replacement therapy and other risk factors), it is recommended to use Janus kinase inhibitors therapeutically only if there are no suitable treatment alternatives. To facilitate a pragmatic and thorough detection of high-risk patients in everyday clinical practice, an interdisciplinary checklist was developed that is suitable as a working tool from the perspective of the dermatologist. | eng |
dc.language.iso | eng | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.subject.ddc | 610 | - |
dc.title | Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases | eng |
dc.type | Article | - |
local.versionType | publishedVersion | - |
local.bibliographicCitation.journaltitle | Journal der Deutschen Dermatologischen Gesellschaft | - |
local.bibliographicCitation.volume | 21 | - |
local.bibliographicCitation.issue | 8 | - |
local.bibliographicCitation.pagestart | 845 | - |
local.bibliographicCitation.pageend | 851 | - |
local.bibliographicCitation.publishername | Wiley-Blackwell | - |
local.bibliographicCitation.publisherplace | Berlin | - |
local.bibliographicCitation.doi | 10.1111/ddg.15136 | - |
local.subject.keywords | Benefit-risk-ratio, carcinogenic risk, cardiovascular risk, infection risk, Janus kinase inhibitors, safety,side effects, thromboembolic risk | - |
local.openaccess | true | - |
dc.identifier.ppn | 185387518X | - |
cbs.publication.displayform | 2023 | - |
local.bibliographicCitation.year | 2023 | - |
cbs.sru.importDate | 2024-03-05T07:22:30Z | - |
local.bibliographicCitation | Enthalten in Journal der Deutschen Dermatologischen Gesellschaft - Berlin : Wiley-Blackwell, 2003 | - |
local.accessrights.dnb | free | - |
Enthalten in den Sammlungen: | Open Access Publikationen der MLU |
Dateien zu dieser Ressource:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
J Deutsche Derma Gesell - 2023 - Wohlrab - Recommendations for risk minimization when using Janus kinase inhibitors for the.pdf | 3.2 MB | Adobe PDF | ![]() Öffnen/Anzeigen |